The use of a stably expressed FRET biosensor for determining the potency of cancer drugs
Related Experiment Video
Updated: Apr 24, 2026
FRET Microscopy for Real-time Monitoring of Signaling Events in Live Cells Using Unimolecular Biosensors
Published on: August 20, 2012
William P Bozza1, Xu Di1, Kazuyo Takeda2
1Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, United States of America.
Abstract:
Many cancer drugs are intended to kill cancer cells by inducing apoptosis. However, the potency assays used for measuring the bioactivity of these products are generally cell viability assays which do not distinguish between cell death and growth inhibition. Here we describe a cell-based fluorescence resonance energy transfer (FRET) biosensor designed to measure the bioactivity of apoptosis inducing cancer drugs. The biosensor contains cyan fluorescent protein (CFP) linked via caspase 3 and caspase 8 specific cleavage recognition sequences to yellow fluorescent protein (YFP). Upon caspase activation, as in the case of apoptosis induction, the linker is cleaved abolishing the cellular FRET signal. This assay closely reflects the mechanism of action of cancer drugs, in killing cancer cells and therefore can function as a potency test for different cancer drugs. We rigorously demonstrate this through characterization of a class of proteins targeting the death receptors. The one-step assay appears to be superior to other apoptosis-based assays because of its simplicity, convenience, and robustness.
Insights
This study introduces a novel fluorescence resonance energy transfer (FRET) biosensor to accurately measure cancer drug potency by detecting apoptosis, or programmed cell death, unlike traditional viability assays.
Area of Science:
- Biochemistry
- Molecular Biology
- Cancer Therapeutics
Background:
- Current cancer drug potency assays often rely on cell viability, which cannot differentiate between growth inhibition and actual cell death.
- Accurate measurement of apoptosis is crucial for understanding cancer drug efficacy.
Purpose of the Study:
- To develop and validate a novel cell-based fluorescence resonance energy transfer (FRET) biosensor for measuring the bioactivity of apoptosis-inducing cancer drugs.
- To provide a more accurate potency assay that directly reflects the mechanism of action of these drugs.
Main Methods:
- A FRET biosensor was engineered, comprising cyan fluorescent protein (CFP) linked to yellow fluorescent protein (YFP) via caspase-specific cleavage sequences.
- Apoptosis induction leads to caspase activation, cleaving the linker and abolishing the FRET signal.
- The biosensor's performance was validated using cancer drugs targeting death receptors.
Main Results:
- The FRET biosensor effectively detects caspase activation, a key event in apoptosis.
- Cleavage of the biosensor linker by activated caspases results in a measurable decrease in the FRET signal.
- The assay demonstrated robustness and accuracy in characterizing apoptosis-inducing agents.
Conclusions:
- The developed FRET biosensor offers a sensitive and specific method for assessing the potency of apoptosis-inducing cancer drugs.
- This assay provides a more direct measure of drug-induced cell death compared to conventional viability assays.
- The simplicity, convenience, and robustness of this one-step assay make it a superior alternative for apoptosis-based drug evaluation.
